Using Janus kinase inhibitors in myeloproliferative neoplasms For patients with myeloproliferative neoplasms, Janus kinase inhibitors can potentially improve symptoms and disease control, but there are a number of safety considerations pharmacists need to be aware of.…
More than 1 million contraception appointments delivered by pharmacies in six months The 1,007,415 pharmacy contraception service consultations included 375,040 emergency hormonal contraception consultations.…
MHRA approves first lower-carbon pressurised metered dose inhalers for asthma The Medicines and Healthcare products Regulatory Agency said that the new versions of the Clenil Modulite 100mcg and 200mcg asthma inhalers have a lower carbon footprint compared with older propellants.…
Members of the public recruited as Pharmacy First ambassadors Under this NHS Cornwall and Isles of Scilly and NHS Devon-led initiative, ambassadors will help spread awareness of Pharmacy First services by sharing their own experiences.…
Post-finasteride syndrome: pharmacists must lead the conversation on patient safety We would not accept a tooth-whitening procedure that carried a risk of suicide, persistent sexual dysfunction and irreversible neurological harm. Why is it being accepted with finasteride?…
Switching between weight-loss medications This article proposes practical approaches for safe, effective switching between tirzepatide and semaglutide.…
Health news round-up: coffee, ADHD prescribing, and GLP-1s and hair loss The Pharmaceutical Journal’s weekly summary of the important developments in pharmacy and health news you may have missed.…
NHS England could mobilise pharmacists in mass casualty incidents under new framework According to its framework on the management of mass casualty incidents, NHS England said that community pharmacies would offer support to people who go directly to pharmacies with minor injuries or health concerns following such an event.…
People with MS in England to be given fampridine as patent expires Fampridine, taken twice daily, improves nerve signalling and walking speed in some patients with multiple sclerosis.…
Novo Nordisk sues Eli Lilly over ‘misleading’ GLP-1 advertising Novo Nordisk claims that Lilly’s advertising campaigns intentionally used outdated studies to offer “proof of broad, product-level superiority” of its Zepbound and Mounjaro products over Novo Nordisk’s Wegovy and Ozempic products.…
